Literature DB >> 2760818

Hepatic drug clearance in children: studies with indocyanine green as a model substrate.

W E Evans1, M V Relling, S de Graaf, J H Rodman, J A Pieper, M L Christensen, W R Crom.   

Abstract

For several drugs metabolized by the liver, higher dosages (mg/kg body weight) are required in children to attain serum concentrations comparable to those in adults. Indocyanine green (ICG), a commonly used model substrate for hepatic elimination of high intrinsic clearance drugs, has been extensively evaluated in adults but not in children. We evaluated the disposition of ICG in 115 children with leukemia and nine healthy adult volunteers. The mean (SD) ICG plasma clearance (CLp) for all 115 children (age 0.9-17.8 years) was significantly greater (p = 0.0006) than for adults [14.8 (7.8) versus 10.6 (2.4) mL/min/kg]. When clearances from only children less than 10 years of age (N = 85) were compared with those from adults, the difference was even greater [15.6 (7.3) versus 10.6 (2.4) mL/min/kg; p = 0.0001]. However, when ICG CLp was normalized to body surface area, values for children did not differ significantly from adults [378 (204) versus 422 (102) mL/min/m2]. These data provide insight as to why dosage (mg/kg) requirements of certain drugs are higher in children.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2760818     DOI: 10.1002/jps.2600780605

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  14 in total

1.  Intravenous Thrombolysis at 3.5 Hours From Onset of Pediatric Acute Ischemic Stroke.

Authors:  Elizabeth D Waring; Truman J Milling; Steven Warach
Journal:  Pediatr Emerg Care       Date:  2020-01       Impact factor: 1.454

Review 2.  Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.

Authors:  Imke H Bartelink; Carin M A Rademaker; Alfred F A M Schobben; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Clearance of Indocyanine Green in Severe Pediatric Burns.

Authors:  Eva C Diaz; David Newcomb Herndon; Mario Alberto Cleves; Ronald P Mlcak; Asle Aarsland; Elisabet Børsheim
Journal:  J Trauma Acute Care Surg       Date:  2019-05       Impact factor: 3.313

Review 4.  Age-related changes in the gastrointestinal system. Effects on drug therapy.

Authors:  F L Iber; P A Murphy; E S Connor
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

5.  RNA-Seq reveals different mRNA abundance of transporters and their alternative transcript isoforms during liver development.

Authors:  Julia Yue Cui; Sumedha S Gunewardena; Byunggil Yoo; Jie Liu; Helen J Renaud; Hong Lu; Xiao-bo Zhong; Curtis D Klaassen
Journal:  Toxicol Sci       Date:  2012-03-27       Impact factor: 4.849

6.  Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.

Authors:  Trevor N Johnson; Amin Rostami-Hodjegan; Geoffrey T Tucker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

7.  Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure.

Authors:  Stefanie Albers; Bernd Meibohm; Thomas S Mir; Stephanie Läer
Journal:  Br J Clin Pharmacol       Date:  2007-11-08       Impact factor: 4.335

8.  Effects of body size and gender on the population pharmacokinetics of artesunate and its active metabolite dihydroartemisinin in pediatric malaria patients.

Authors:  Carrie A Morris; Beesan Tan; Stephan Duparc; Isabelle Borghini-Fuhrer; Donald Jung; Chang-Sik Shin; Lawrence Fleckenstein
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

Review 9.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 10.  Lean body mass as a predictor of drug dosage. Implications for drug therapy.

Authors:  D J Morgan; K M Bray
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.